Search This Blog

Thursday, January 4, 2024

Xeris Biopharma Updates Its Outlook for 2023

 Company expects to be cashflow positive for the fourth quarter, report total revenue at the high end of its previous guidance of $160M-$165M, and end 2023 with over $72M in cash, cash equivalents, and short-term investments, exceeding its previous guidance of $65M-$70M

Company to report Q4 and FY 2023 financial results on or about March 6, 2024

https://www.businesswire.com/news/home/20240104585894/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.